191 related articles for article (PubMed ID: 12918543)
1. Implantable defibrillator therapy.
Alings AM
Neth J Med; 2003 May; 61(5 Suppl):4-7. PubMed ID: 12918543
[TBL] [Abstract][Full Text] [Related]
2. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator.
Prystowsky EN
Rev Cardiovasc Med; 2001; 2(4):197-205. PubMed ID: 12439369
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
[TBL] [Abstract][Full Text] [Related]
4. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
[TBL] [Abstract][Full Text] [Related]
5. Ventricular tachycardia and sudden cardiac death.
Reddy PC; Tandon N; Stafford PR
J La State Med Soc; 1999 May; 151(5):281-7. PubMed ID: 10363484
[TBL] [Abstract][Full Text] [Related]
6. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death.
Klein MH; Gold MR
Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188
[TBL] [Abstract][Full Text] [Related]
7. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
[TBL] [Abstract][Full Text] [Related]
8. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
[TBL] [Abstract][Full Text] [Related]
9. [Primary prevention of sudden cardiac death implanted cardioverter defibrillator (ICD) versus antiarrhythmic drugs].
Iturralde Torres P
Arch Cardiol Mex; 2007; 77 Suppl 4():S4-129-32. PubMed ID: 18938711
[TBL] [Abstract][Full Text] [Related]
10. [Implantable cardioverter-defibrillator(ICD)].
Kurita T
Nihon Rinsho; 2002 Jul; 60(7):1353-60. PubMed ID: 12136614
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
[TBL] [Abstract][Full Text] [Related]
12. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
13. [Indications for the implantable cardiac defibrillator].
Ben Ameur Y; Baraket F; Terras M; Longo S; Kraiem S; Hmem M; Slimane ML
Tunis Med; 2003; 81 Suppl 8():601-12. PubMed ID: 14608747
[TBL] [Abstract][Full Text] [Related]
14. Role of drugs and devices in patients at risk of sudden cardiac death.
Boriani G; Diemberger I; Valzania C; Biffi M; Martignani C; Raschi E; Mantovani V; Ziacchi M; Bertini M; De Ponti F; Branzi A
Fundam Clin Pharmacol; 2010 Oct; 24(5):575-94. PubMed ID: 20608989
[TBL] [Abstract][Full Text] [Related]
15. [The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
Alboni P
Ital Heart J Suppl; 2002 Mar; 3(3):337-43. PubMed ID: 12040849
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with the implantable cardioverter defibrillator (ICD)].
Jordaens LJ
Verh K Acad Geneeskd Belg; 1997; 59(2):107-33. PubMed ID: 9210850
[TBL] [Abstract][Full Text] [Related]
17. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
Wilkoff BL;
Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
[TBL] [Abstract][Full Text] [Related]
18. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.
Backenköhler U; Erdogan A; Steen-Mueller MK; Kuhlmann C; Most A; Schaefer C; Stertmann W; Waas W; Tillmanns H; Waldecker B
J Cardiovasc Electrophysiol; 2005 May; 16(5):478-82. PubMed ID: 15877617
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
Das MK; Zipes DP
J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT.
Grimm W; Alter P; Maisch B
Herz; 2004 May; 29(3):348-52. PubMed ID: 15167963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
